In another study, the BRAF V600E mutation was found to be significantly associated with the expression of CD34 in 38/93 (40,8%) of ganglioglioma [56], confirming the quality of CD34 immunoreactivity as surrogate marker for GG and PXA [5, 60]. The gene discussed is BRAF; the disease is ganglioglioma.